How the HPV Vaccine is Eradicating Cervical Cancer—and Why the Final Mile is the Hardest

For the first time in recorded history, a demographic of women has achieved a zero percent mortality rate from cervical cancer. According to a landmark study published this week in The Lancet, not a single woman aged 20 to 24 died from the disease in England between 2020 and 2024. This unprecedented milestone is the direct result of a national immunization campaign that began when those women were young girls.[1][5]

The data offers one of the most striking validations of a public health intervention in modern medicine. Researchers estimate that without the human papillomavirus (HPV) vaccine, approximately 23 deaths would have been expected in that age cohort over the five-year period. Instead, the mortality reduction hit exactly 100 percent. For women vaccinated at ages 12 or 13, the risk of dying from cervical cancer before the age of 30 has been effectively reduced to zero.[1]

To understand the magnitude of this achievement, it is necessary to understand the unique pathology of cervical cancer. Unlike many cancers that arise from complex genetic and environmental factors, cervical cancer has a single, overwhelming culprit: HPV. The virus, which is transmitted through close skin-to-skin contact, is responsible for 99 percent of all cervical cancer cases. While most HPV infections clear naturally, persistent infections with high-risk strains can cause abnormal cellular changes that slowly develop into invasive cancer over years or decades.[5][6]

England introduced its national HPV vaccination program in 2008, initially targeting girls aged 12 to 13. Because cervical cancer typically takes years to develop, epidemiologists knew they would have to wait over a decade to see the vaccine's ultimate impact on mortality rates. The new Lancet data represents the culmination of that waiting period, proving that neutralizing the virus before sexual debut stops the cancer pipeline at its source.[1][6]

The success in the United Kingdom mirrors data emerging from the United States. The Centers for Disease Control and Prevention reports that since the vaccine's introduction in 2006, infections with the HPV types that cause most cancers have plummeted by 88 percent among teenage girls and 81 percent among young adult women. Correspondingly, the rate of cervical precancers—the immediate precursor to the disease—has dropped by 80 percent in vaccinated populations.[3]

These overwhelming efficacy numbers have emboldened the World Health Organization to launch a global eradication campaign. The WHO's "90-70-90" strategy aims to have 90 percent of girls fully vaccinated by age 15, 70 percent of women screened with high-performance tests by ages 35 and 45, and 90 percent of women with cervical disease receiving treatment by 2030. If these targets are met, the WHO projects that cervical cancer could be eliminated as a public health problem—defined as fewer than 4 cases per 100,000 women—within the next century.[2]

A recent clinical breakthrough is making that global target significantly more achievable. A major trial funded by the National Institutes of Health and conducted in Costa Rica demonstrated that a single dose of the HPV vaccine is at least 97 percent effective at preventing persistent infections of high-risk strains over a five-year period. This efficacy is statistically comparable to the traditional two-dose regimen. For low- and middle-income countries, where logistical and financial barriers often derail multi-dose schedules, the viability of a "one-and-done" shot is a game-changer.[4]

Yet, despite the scientific triumphs, the final mile of eradication faces steep behavioral and political headwinds. In England, the very country celebrating the zero-mortality milestone, vaccine uptake has slipped alarmingly since the COVID-19 pandemic. National coverage has fallen to roughly 75 percent, with rates in London dropping as low as 60 percent. Public health officials warn that this backsliding threatens to reverse the historic gains.[5]

Cancer Research UK, which funded the Lancet study, has sounded the alarm over these declining numbers. The organization's leadership emphasized that while the vaccine is a powerful example of what is possible when science is backed by strong public health programs, the protection only works if the shots actually reach arms. Epidemiologists estimate that the current dip in uptake could result in dozens of avoidable deaths each year if pre-pandemic vaccination levels are not restored.[1][5]

In the United States, the challenge is increasingly political. The Advisory Committee on Immunization Practices (ACIP), which guides CDC vaccine schedules, was recently reconstituted under Health and Human Services Secretary Robert F. Kennedy Jr. The new committee has announced a multi-year "comprehensive review" of the HPV vaccine's efficacy and safety. Medical analysts warn that subjecting a vaccine with over 135 million safely administered doses to a highly publicized re-evaluation risks manufacturing uncertainty and further depressing uptake.[6]

The stakes of this hesitancy extend beyond cervical cancer. The HPV vaccine also provides robust protection against several other malignancies linked to the virus, including cancers of the anus, penis, vagina, vulva, and the oropharynx (the back of the throat). In fact, head and neck cancers have recently surpassed cervical cancer as the most common HPV-associated malignancy in the United States, underscoring the critical importance of vaccinating boys as well as girls.[3][5]

Ultimately, the story of the HPV vaccine is one of profound scientific success colliding with human complexity. Researchers have delivered a medical miracle: a simple injection that effectively deletes a deadly cancer from the human experience. The remaining question is no longer whether the tool works, but whether global societies have the sustained focus and trust required to use it.[6]